Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its ...
Novo Shares Fall After CagriSema Results in Diabetes Patients
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight ...
Devdiscourse49m
Novo Nordisk's CagriSema: A Breakthrough in Obesity Treatment for Diabetics
Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...
pharmaphorum55m
Changing Faces: Pharma and biotech hires – February 2025
February is the shortest month, but there was still plenty of time for a rush of pharma and biotech hires, including a number ...